For IgA+IGLC2+ plasma cells, allograft rejection, interferon‐alpha response, interferon‐gamma response, and inflammatory response were enhanced in the tumor‐derived cells, indicating the involvement in promoting inflammatory responses in tumors. The gene discussed is CD79A; the disease is neoplasm.